Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its stock price in recent months.

Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings report.

An AI collaboration boosted the company behind the largest U.S. cloud service on Monday, Nov. 3, 2025, while shares of the two companies involved in a consumer goods deal saw major moves.

The announcement comes just weeks after President Trump publicly spread debunked claims that Tylenol consumption is linked to autism.

Kenvue stock share price today shows a major surge after Kimberly-Clark announced plans to buy Kenvue for over $40 billion. The cash-and-stock deal will merge brands like Huggies, Kleenex, Tylenol, and Band-Aid under one company,

Kenvue faces declining sales and high debt post-spin-off. Read why a dividend cut may be imminent and why KVUE stock is a Sell.